The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this therapy for elderly patients aged ≥75 years and to clarify whether an extremely high sustained virological response (SVR) rate can be achieved, even in a real-world setting when patients with resistance-associated substitutions (RASs) to nonstructural protein 5A (NS5A) inhibitors or prior simeprevir failure are excluded. Methods: Daclatasvir (60 mg) and asunaprevir (100 mg) were orally administered daily for 24 weeks. Patients without pre-existing NS5A RASs and simeprevir failure were enrolled in this study. Results: Overall, 110 patients were treated. The median age was 73 years old. The SVR rates of total patients, those aged ≥75 years, and those aged <75 years were 97% (107/110), 98% (46/47), and 97% (61/63), respectively. The treatment of two patients (2%) was discontinued because of adverse events. Conclusions: Daclatasvir with asunaprevir was a safe treatment, even in patients aged ≥75 years. When patients without pre-existing NS5A RASs and prior simeprevir failure were selected, an extremely high SVR rate could be achieved irrespective of age.
Abstract
Background/Aims: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this therapy for elderly patients aged ≥75 years and to clarify whether an extremely high sustained virological response (SVR) rate can be achieved, even in a real-world setting when patients with resistance-associated substitutions (RASs) to nonstructural protein 5A (NS5A) inhibitors or prior simeprevir failure are excluded. Methods: Daclatasvir (60 mg) and asunaprevir (100 mg) were orally administered daily for 24 weeks. Patients without pre-existing NS5A RASs and simeprevir failure were enrolled in this study. Results: Overall, 110 patients were treated. The median age was 73 years old. The SVR rates of total patients, those aged ≥75 years, and those aged <75 years were 97% (107/110), 98% (46/47), and 97% (61/63), respectively. The treatment of two patients (2%) was discontinued because of adverse events. Conclusions: Daclatasvir with asunaprevir was a safe treatment, even in patients aged ≥75 years. When patients without pre-existing NS5A RASs and prior simeprevir failure were selected, an extremely high SVR rate could be achieved irrespective of age.
참고문헌 (23)
- Asahina Y, "Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection", Hepatology, 52, pp.518~527 (2010)[DOI]
- Editors of the Drafting Committee for Hepatitis Management Guidelines, "Guidelines for the management of hepatitis C virus infection: first edition, May 2012, The Japan Society of Hepatology", Hepatol Res, 43, pp.1~34 (2013)[DOI]
- Tamai H, "Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation", Hepatol Res, 41, pp.1137~1144 (2011)[DOI]
- Tamai H, "Low-dose pegylated interferon-<TEX>${\alpha}2a$<", TEX> plus ribavirin therapy for elderly and, Antivir Ther, pp.2014, 19[DOI]
- Kumada H, "Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan", J Hepatol, 56, pp.78~84 (2012)[DOI]
- Hayashi N, "Simeprevir with peginterferon", ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial, 2014, pp.61, 219~227
- Tamai H, "Prediction of sustained virological response to telaprevir-based triple therapy using viral response within 2 weeks", Hepat Res Treat, 2014, pp.748935~ (2014)
- Kumada H, "Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection", Hepatology, 59, pp.2083~2091 (2014)[DOI]
- Kanda T, "Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan", Int J Med Sci, 13, pp.418~423 (2016)[DOI]
- Manns M, "All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study", Lancet, 384, pp.1597~1605 (2014)[DOI]
- Ogawa E, "Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis", Hepatol Res, 47, pp.E120~E131 (2017)[DOI]
- Morio R, "Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C", J Gastroenterol, 52, pp.504~511 (2017)[DOI]
- Morio K, "Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients", J Gastroenterol Hepatol, 32, pp.645~650 (2017)[DOI]
- Iio E, "Efficacy of daclatasvir", asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1, 2017, pp.52, 94~103
- Akuta N, "Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection", J Med Virol, 88, pp.506~511 (2016)[DOI]
- Akuta N, "Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older", J Med Virol, 89, pp.91~98 (2017)[DOI]
- Toyoda H, "Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis", J Gastroenterol, 51, pp.741~747 (2016)[DOI]
- Suda G, "Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment", Hepatol Res, 47, pp.1127~1136 (2017)[DOI]
- Suda G, "Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C", J Gastroenterol, 51, pp.733~740 (2016)[DOI]
- Nakamura Y, "Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction", J Med Virol, 89, pp.665~671 (2017)[DOI]
- Hernandez D, "Impact of pre-existing NS5A-L31 or -Y93H minor variants on response rates in patients infected with HCV genotype-1b treated with daclatasvir", asunaprevir, 2016, pp.33, 1169~1179
- Ikeda H, "Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir", asunaprevir, 2017, pp.89, 99~105
- Uchida Y, "Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir", asunaprevir therapy by a two-hit mechanism, 2016, pp.46, 1234~1246